Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors

G. Scambia1, L. Catozzi2, P. Benedetti Panic1, G. Ferrandina1, G. Almadori1, G. Paludetti3, G. Cadoni3, M. Distefano1, A. Piffanelli2, S. Mancuso1 & M. Maurizi1

1Department of Obstetrics and Gynecology, Catholic University, Rome, Italy; 2Department of Radiology, University of Ferrara, Ferrara, Italy; 3Department of Otolaryngology, Catholic University, Rome, Italy

Summary
Western blotting analysis of the p21 ras oncoprotein was performed in seven normal laryngeal mucosa specimens and 43 primary laryngeal cancers. Varying p21 levels, expressed as optical density (OD), were found in normal mucosa (median 1.84 OD, range 0.90–2.17 OD) and in primary laryngeal tumours (median 1.74 OD, range 0.30–6.37 OD). When p21 expression in laryngeal cancer was compared with the normal counterpart, higher levels were found in neoplastic than in normal laryngeal tissue (median 2.54 OD, range 1.76–6.37 OD, vs median 1.94 OD, range 0.90–2.17 OD) (P = 0.023). Immunohistochemical analysis demonstrated that most of the tumour cells (more than 70%) were immunostained while the stromal component was unreactive. No correlation between p21 expression and tumour location, stage and histopathological grade was observed. The correlation between ras p21 protein expression and epidermal growth factor receptor (EGFR) levels was also investigated. EGFR-positive cases did not show any difference in p21 expression with respect to EGFR-negative cases (median 1.52 OD, range 0.30–6.37 OD, vs median 1.84 OD, range 0.93–3.71 OD). Our findings suggest that overexpression of p21 protein is associated with a malignant phenotype in laryngeal cancer. Further studies should be undertaken to evaluate whether the assessment of p21 protein expression may have clinical significance in laryngeal cancer.

Laryngeal cancer constitutes up to 2% of all cancers, and 90–95% are squamous cell carcinomas (Powell et al., 1983). The aetiology of laryngeal cancer has yet to be clarified, although it seems to be closely related to alcohol and tobacco abuse. Only now are the molecular changes associated with laryngeal cancer being elucidated.

Several transforming cellular oncogenes have been isolated from a variety of human tumours, and their characterisation has significantly contributed to an understanding of cancer at the molecular level. In particular, attention has been focused on the ras gene family, which consists of three functional genes encoding a 21 kDa protein located on the inner surface of the plasma membrane and characterised by a guanosine 5′-triphosphatase activity (Barbacid, 1987).

The normal function of p21 has been partially clarified in yeast Saccharomyces cerevisiae (Hughes et al., 1990) but is still unknown in mammals; however, because of some structural similarity to the so-called G-proteins acting as ‘signal transducers’ (Gilman, 1984), it has been suggested that the p21 protein may be involved in the transduction of extracellular signals controlling cell growth.

The finding that epidermal growth factor (EGF), a peptide acting through a specific plasma membrane receptor (EGFR) (Carpenter, 1987), increases the level of the active p21–GTP complex in ras oncogene-transformed cells suggests that the biological effects induced by EGF, like those induced by platelet-derived growth factor, may be associated with p21 oncoprotein activation (Satoh et al., 1990).

Previous studies have reported enhanced p21 expression in human bladder (Viola et al., 1985), lung (Kurzrock et al., 1986), breast (Walker et al., 1988), ovarian (Rodenburg et al., 1988; Scambia et al., 1993a), endometrial (Long et al., 1988; Scambia et al., 1992a) and squamous cell cancers (Tanaka et al., 1986; Satoh et al., 1992). Moreover, activation of the ras oncogene by mutation at amino acid position 12, 13 or 61, or amplification of the gene product, has been demonstrated in different tumour types (Spanidios, 1987; Smit et al., 1988; vant’ Veer et al., 1988; Volgelstein et al., 1988; Boltz et al., 1989). At present very few data are available on ras p21 expression in laryngeal cancer.

Previous studies analysing the alterations of ras at the gene level did not demonstrate amplification or rearrangement, while mRNA overexpression was observed in 22% of cases (Sheng et al., 1990). The aim of the study was to assess the expression of the p21 oncoprotein in normal and malignant laryngeal tissues by using the Western blotting technique. The correlation between p21 levels and histopathological parameters and the distribution of p21 levels according to EGFR status were also analysed.

Materials and methods

Tissue samples
The study included seven normal mucosa specimens and 43 primary human laryngeal tumours.

Thirty-nine of the tumour patients were males and four were females. Patients were aged between 34 and 80 years (median age 61 years). All tumours were histologically squamous epithelial carcinomas. Tumour site was classified as glottic or supraglottic and was defined as transglottic when the extension of disease did not permit identification of the origin of the tumour. Tumours were staged according to TNM classification (American Joint Committee on Cancer, 1993) and histologically graded as well- (G1), moderately (G2) and poorly (G3) differentiated tumours.

Twenty-three patients underwent radical laryngectomy, while 20 had conservative surgery (16 supraglottic laryngectomies, two cordectomies, two hemilaryngectomies). Fifteen patients in whom there was lymph node involvement underwent therapeutic neck dissection.

The characteristics of the tumour patients are summarised in Table I.

Expression of the p21 protein was also analysed in seven normal laryngeal mucosa specimens obtained from the same tumour patients in a corresponding non-tumour area of the larynx. At the time of surgery a representative specimen of normal tissue was set aside for histopathological examination. The specimens were frozen immediately in liquid nitro-
Table I Patient characteristics

| No. of patients (%) |
|---------------------|
| Total               | 43 |
| Sex                 |     |
| Male                | 39 (91) |
| Female              | 4 (9) |
| Age (years)         |     |
| <60                 | 18 (42) |
| >60                 | 25 (58) |
| Tumour location     |     |
| Supraglottic        | 19 (44) |
| Glottic             | 11 (26) |
| Transglottic        | 13 (30) |
| Stage*              |     |
| I                   | 11 (26) |
| II                  | 12 (28) |
| III                 | 14 (32) |
| IV                  | 6 (14) |
| Lymph node involvement |     |
| No                  | 28 (65) |
| Yes                 | 15 (35) |
| Histopathological gradeb |   |
| G1                  | 3 (7) |
| G2                  | 28 (65) |
| G3                  | 12 (28) |
| Type of surgery     |     |
| Conservative        | 20 (46) |
| Radical             | 23 (54) |

*Stage I = T1; N0, M0; II = T2, N0, M0; III = T1, 2, 3, N0, M0; IV = T4, N0, 1, M0, or any T, N2, 3, M0, or any T, any N, M1 (American Joint Committee on Cancer, 1993).

Preparation of the tissue lysates

Frozen tissues were pulverised and homogenised with five volumes of ice-cold buffer consisting of 0.1M sodium chloride, 5mM magnesium chloride, 1% Nonidet P-40, 0.5% sodium deoxycholate, 2 units of kallikrein inhibitor per ml of (bovine) aprotinin and 20 mM Tris–HCl, pH 7.4. The homogenate was centrifuged at 750 g for 20 min at 4°C and the resulting supernatants were frozen at −80°C until assay.

Detection and estimation of the p21 protein

The Western blotting technique was used for p21 protein determination (De Bortoli et al., 1985). After 3 min boiling, lysate proteins were separated by 12% sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis. The gels were transblotted to nitrocellulose filters in Tris–glycine buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 7.4) for 5 h at 60 V. Nitrocellulose sheets were washed and unoc-cupied binding sites were saturated with 3% bovine serum albumin in NTE–NP40 (50 mM Tris–HCl pH 7.5, 2 mM EDTA, 150 mM sodium chloride, 0.1% Nonidet P-40) for 3 h at 37°C. Then the filters were sequentially incubated with buffer containing Y13-259 rat monoclonal antibody (Furth et al., 1982) (diluted 1:300) directed against Ha-MUSV-encoded p21 for 4 h at 4°C, and with rabbit anti-rat IgG (diluted 1:500) and 5 × 10E5 c.p.m. ml−1 [35S]-labelled protein A for 1 h at 4°C. Filters were air dried and exposed to Kodak XAR films for 48 h at −80°C. Comparison of the resulting autoradiographs with others in which normal rat serum was substituted for p21 monoclonal antibody permitted the identification of the p21 band. Computer-assisted image analysis of autoradiographs was performed in order to quantify the intensity of the bands. In order to standardise the analysis, a constant amount (100 µg) of protein of every sample was loaded on SDS gels. In addition a control p21 derived from NRK (normal rat kidney) cells transformed by Harvey murine sarcoma virus was used in all experiments.

In order to better ensure that the p21 kDa band we detected was the ras p21 oncoprotein, an experiment was carried out (Figure 1) in which normal rat serum was used instead of specific anti-p21 Y13-259 MAb. The band of 21 kDa was absent when normal rat serum was utilised. Optical densitometric values of the band intensities (the integral of the absorbance) (OD) were used for statistical analysis. Western blotting analysis was performed in different specimens of the same tumour sample revealing an intra-tumour homogeneity of p21 expression (coefficient of variation 14%). Intra-sample variation of OD readings ranged from 2 to 3.8%. The cut-off utilised to define p21 status was 2.00 OD, corresponding to the median value of p21 in laryngeal carcinomas.

Figure 1 Western blotting analysis of p21 oncoprotein in the same six patients with primary laryngeal cancer incubated with specific anti-p21 Y13-259 MAb a, or with normal rat serum b. Lane S: molecular weight standards.

Figure 2 Western blotting analysis of p21 oncoprotein in normal laryngeal mucosa specimens (lanes 1–3) and neoplastic laryngeal tumours (lanes 4–13). Lane S: molecular weight standards.
EGFR measurement

An aliquot of the pulverised tissues was homogenised in ice-cold buffer consisting of 25 mM Tris, 1.5 mM sodium azide, 10 mM monothioglycerol and 20% glycerol (TENG). Cytosol and membrane fractions were prepared as previously described (Battaglia et al., 1988). The crude homogenate was centrifuged at 7,000 g for 20 min at 0°C. The supernatants were then centrifuged at 105,000 g for 75 min at 0°C.

The membrane pellet was resuspended in 25 mM Tris, 1.5 mM EDTA, 5 mM sodium azide (NaN3), 20% glycerol and 10 mM magnesium chloride (TENG + magnesium chloride). Aliquots of the suspension (100 μL containing 300–500 μg of protein) were incubated with [125I]EGF (NEN Dupont De Nemours) (specific activity 780,000 Ci mmol⁻¹ (3.2 nm) in the presence or absence of unlabelled EGF (Boehringer Mannheim, Germany) (1 μM) for 16 h at room temperature in a final volume of 400 μL. Binding was stopped by addition of 3 mL of 25 mM Tris, 20% glycerol, 5 mM and 0.1% bovine serum albumin. Pellets were obtained by centrifugation at 2,000 g for 20 min at 0°C and counted in a gamma-counter for 1 min. Results were expressed as femtomoles per mg of membrane protein (fmol mg⁻¹ protein). EGFR status was defined using a cut-off of 8.00 fmol mg⁻¹ protein, corresponding to the median EGFR levels of laryngeal carcinomas (data not shown).

Immunohistochemical staining

Immunohistochemical analysis of the p21 protein was performed by the avidin–biotin–peroxidase complex (ABC) method (Vector Laboratories, Burlingame, CA, USA) with the Y13-259 anti-human p21 rat monoclonal antibody (MAb) (Oncogene Science). For this purpose a representative sample of each tumour was fixed according to routine laboratory procedures in 10% buffered formalin (pH 7.4) and embedded in paraffin wax. Five micron sections were dewaxed, rehydrated, washed in phosphate-buffered saline (PBS) solution and then incubated for 5 min in 3% (w/v) hydrogen peroxide solution at room temperature to block any endogenous peroxidase. All sections were washed again in PBS solution and incubated with normal serum as the blocking reagent to minimise non-specific binding. A 1:100 dilution of the monoclonal antibody specific for p21 was applied to the specimen. Normal rat IgG (Sigma, St Louis, MO, USA) was used (1:100 in PBS) as a negative control. The sections were subsequently incubated with the biotinylated horse anti-rat IgG (1:200 in PBS), and with the ABC reagent for 30 min at room temperature. Finally, the sections were washed in PBS, stained by incubation with 0.5 mg ml⁻¹ 3,3'-diaminobenzidine (Sigma) in 0.01% hydrogen peroxide for 5 min, and counterstained with haematoxylin.

Statistical analysis

Student’s t-test was used to analyse the distribution of p21 oncoprotein in normal and neoplastic laryngeal tissues. Since p21 levels are not normally distributed, the Mann–Whitney rank-sum non-parametric test was used to analyse p21 expression according to the histopathological parameters of the cancer patients and EGFR expression.
Results

Figure 2 shows a representative example of Western blotting analysis of the p21 oncoprotein in normal and neoplastic laryngeal tissues. We found that both normal and neoplastic tissues contained detectable amounts of p21.

In Figure 3 the p21 immunohistochemical staining of primary laryngeal cancer is shown. The immunoreaction of p21 was heterogeneous. However, most of the cancer cells (more than 70%) were p21 positive, while the stromal component was unreactive. The specific p21 staining is seen as diffusely located in the cytoplasm of the tumour cells.

The densitometric evaluation of p21 levels in normal and neoplastic laryngeal tissues is shown in Figure 4. Scattered p21 OD values were found in normal mucosa (median 1.94 OD, range 0.90–2.17 OD) and in primary laryngeal tumours (median 1.74 OD, range 0.30–6.37 OD). When p21 expression in laryngeal cancer was compared with the normal counterpart, higher levels were found in neoplastic than in normal laryngeal tissue (median 2.54 OD, range 1.76–6.37 OD vs median 1.94 OD, range 0.90–2.17 OD) (P = 0.023).

In Table II the distribution of densitometric p21 values according to histopathological characteristics of 43 primary laryngeal tumours is shown. No correlation between p21 expression and tumour location, stage of disease or histopathological grade was observed.

No correlation was found between EGFR levels and p21 densitometric band intensities (data not shown). Moreover we investigated the distribution of p21 OD values according to EGFR status, which was defined using a cut-off of 8.00 fmol mg⁻¹ protein. This value corresponds to the median value of EGFR levels in our tumour series and was previously demonstrated (Maurizi et al., 1992) to be the best discriminating value.

EGFR-positive cases do not show any significant difference in p21 OD with respect to EGFR-negative cases (median 1.52 OD, range 0.30–6.37 OD vs median 1.84, range 0.93–3.71 OD) (Table III).

Discussion

To our knowledge, this is the first study using the Western blotting technique to analyse p21 protein expression in normal laryngeal tissues and laryngeal tumours.

Varying levels of the p21 protein were observed in normal laryngeal specimens, as reported in other normal tissues (Walker et al., 1988; Scambia et al., 1993a,b), suggesting that p21 may be involved in normal cell functions and metabolism. We found that p21 levels were higher in neoplastic than in normal tissues when samples from the same patients were compared, thus confirming previous observations reported in breast (Spandidos et al., 1984), colon (Gallick et al., 1985), ovarian (Scambia et al., 1993a) and endometrial (Scambia et al., 1993b) tissues. These findings suggest that p21 overexpression may be associated with a malignant phenotype.

As far as laryngeal cancer is concerned, the presence of a wide range of p21 levels supports the hypothesis that overexpression of the p21 protein may play a role in the biology of laryngeal cancer cells, thus characterising more aggressive tumours. ras gene amplification has not been reported until now in laryngeal cancer (Merritt et al., 1990; Sheng et al., 1990). Therefore it is conceivable that transcriptional or post-transcriptional mechanisms are involved in p21 ras overexpression in laryngeal tumour cells. The MAB used in our study recognises both the abnormal and normal products of the three ras genes. The percentage of ras gene mutations has been reported to range from 4 to 14% in head and neck carcinomas (Sheng et al., 1990; Anderson et al., 1992; Irish, 1992), whereas there is no evidence of ras gene mutation in laryngeal tumours (Anderson et al., 1992). It is conceivable that the role of altered p21 protein in laryngeal cancer is irrelevant and that the overexpression of each of the p21 gene products is responsible for ras-induced transformation.

Despite the evidence that the p21 oncoprotein may be involved in mediating EGF mitogenic signals (Kamata & Ferragamo, 1984), ras p21 expression was not related to EGFR levels as previously reported in gynaecological.

Table II Distribution of densitometric p21 band intensities according to histopathological and clinical characteristics of 43 primary laryngeal carcinomas

| No. of patients | Median (OD) | Range (OD) |
|-----------------|-------------|------------|
| Tumour location |             |            |
| Supraglottic    | 19          | 1.78       | 0.30–6.37 |
| Glottic         | 11          | 1.26       | 0.40–3.71 |
| Transglottic    | 13          | 2.11       | 1.03–5.47 |
| Stage           |             |            |
| I               | 11          | 1.80       | 0.83–6.37 |
| II              | 12          | 1.48       | 0.80–2.90 |
| III             | 14          | 1.97       | 0.30–5.47 |
| IV              | 6           | 2.40       | 1.26–4.95 |
| Lymph node involvement | 28 | 1.55 | 0.83–5.47 |
| Yes             | 15          | 1.99       | 0.30–6.37 |
| Histopathological grade | 1992. |
| GI              | 3           | 1.50       | 1.25–1.76 |
| G2              | 28          | 1.84       | 0.83–5.47 |
| G3              | 12          | 1.55       | 0.30–6.37 |

Table III Correlation of p21 oncoprotein expression with EGFR status in 43 primary laryngeal tumours

| No. of patients (%) | p21 expression (OD) | Median | Range | P-value |
|---------------------|---------------------|--------|-------|---------|
| EGFR -               | 22 (51)             | 1.84   | 0.93–3.71 |        |
| EGFR +              | 21 (49)             | 1.52   | 0.30–6.37 | n.s.    |

*8.00 fmol mg⁻¹ protein was used as an arbitrary cut-off to define EGFR status.
tumours (Scambia et al., 1993a, b). It could be suggested that the EGF/EGFR system does not interact with ras or that the two systems are differentially regulated in laryngeal tumours.

The prognostic characterization of laryngeal cancer is still inadequate, and attempts should be made to identify new factors which could give further insight into tumour cell biology and the clinical evolution of this neoplasia.

It has been reported that p21 overexpression is associated with tumour progression and poor prognosis in breast cancer (Clair et al., 1987). Moreover, our data indicate that p21 overexpression may have a negative prognostic value in ovarian cancer (Scambia et al., 1993a).

Since the number of cases examined by us does not allow the evaluation of the possible role of p21 expression in the prognostic characterisation of laryngeal cancer patients, prospective studies are now in progress in our institute.

This study was supported by the special CNR project ACRG.F.G. is the recipient of a fellowship from the Italian Association for Cancer Research ( AIRC).